CDH5 - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	NQO1	NAD(P)H quinone dehydrogenase 1	Regulation of ornithine decarboxylase (ODC)	Menadione Dicoumarol Duroquinone 3-Hydroxymethyl-5-Aziridinyl-1methyl-2-[1h-Indole-4,7-Dione]-Propanol ES-936 Cibacron Blue Flavin adenine dinucleotide 5-Methoxy-1,2-Dimethyl-3-(Phenoxymethyl)Indole-4,7-Dione RH-1 Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone] 3-(HYDROXYMETHYL)-1-METHYL-5-(2-METHYLAZIRIDIN-1-YL)-2-PHENYL-1H-INDOLE-4,7-DIONE Cannabidiol
Novel	CA7	carbonic anhydrase 7	Reversible hydration of carbon dioxide	Ethoxzolamide Benzthiazide Cyclothiazide Methazolamide Hydroflumethiazide Acetazolamide Zonisamide Diclofenamide Ellagic acid
Novel	PYGB	glycogen phosphorylase B	Neutrophil degranulation Glycogen breakdown (glycogenolysis)	Pyridoxal phosphate Alvocidib
Novel	RND3	Rho family GTPase 3		Guanosine-5'-Triphosphate
Novel	CDH1	cadherin 1	Degradation of the extracellular matrix Degradation of the extracellular matrix Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Integrin cell surface interactions Apoptotic cleavage of cell adhesion proteins Adherens junctions interactions RHO GTPases activate IQGAPs InlA-mediated entry of Listeria monocytogenes into host cells		Gastric cancer Penile cancer Nasopharyngeal cancer Breast cancer Hepatocellular carcinoma Thyroid cancer
Novel	CDH16	cadherin 16
Novel	CDH3	cadherin 3	Adherens junctions interactions		Hypotrichosis, congenital, with juvenile macular dystrophy Ectodermal dysplasia, ectrodactyly, and macular dystrophy (EEM syndrome)
	SRC	SRC proto-oncogene, non-receptor tyrosine kinase	Signaling by ERBB2 Nuclear signaling by ERBB4 Downregulation of ERBB4 signaling PIP3 activates AKT signaling GAB1 signalosome Downstream signal transduction Constitutive Signaling by Aberrant PI3K in Cancer Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins G alpha (s) signalling events G alpha (i) signalling events G alpha (i) signalling events DCC mediated attractive signaling DCC mediated attractive signaling Netrin mediated repulsion signals Regulation of commissural axon pathfinding by SLIT and ROBO RAF activation MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PTK2 signaling InlA-mediated entry of Listeria monocytogenes into host cells Regulation of RUNX1 Expression and Activity RUNX2 regulates osteoblast differentiation Regulation of RUNX3 expression and activity Extra-nuclear estrogen signaling Activated NTRK2 signals through FYN Activated NTRK3 signals through PI3K Activated NTRK3 signals through PI3K Long-term potentiation Signaling downstream of RAS mutants Signaling by RAF1 mutants	Dasatinib RU84687 RU79256 N6-Benzyl Adenosine-5'-Diphosphate RU85493 RU78262 Phosphonotyrosine Malonic acid RU83876 RU90395 RU79072 RU78783 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine PASBN 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid PAS219 DPI59 RU82197 Phenylphosphate RU78300 RU79073 RU82209 ISO24 RU85053 RU78299 Oxalic Acid RU78191 Citric acid Paratoulene phosphate 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE Purvalanol A XL228 Tirbanibulin Bosutinib 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL PD-168393 [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile PP-121 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide Ponatinib Nintedanib Fostamatinib
	KDR	kinase insert domain receptor	Neurophilin interactions with VEGF and VEGFR VEGF binds to VEGFR leading to receptor dimerization Integrin cell surface interactions VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway VEGFR2 mediated cell proliferation Signaling by membrane-tethered fusions of PDGFRA or PDGFRB	Sorafenib Sunitinib 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea Cediranib Vatalanib XL999 TG-100801 XL820 CYC116 Ramucirumab Pegdinetanib RAF-265 ABT-869 IMC-1C11 Semaxanib Pazopanib Midostaurin Axitinib 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine Cabozantinib Regorafenib Ponatinib Lenvatinib Nintedanib Fostamatinib Erdafitinib Foretinib Ripretinib Pralsetinib
	EGFR	epidermal growth factor receptor	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus HCMV Early Events Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants	Cetuximab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Alvocidib IGN311 Matuzumab Vandetanib Rindopepimut Canertinib Pelitinib Varlitinib AV-412 S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE PD-168393 Afatinib Osimertinib Necitumumab Foreskin keratinocyte (neonatal) Depatuxizumab mafodotin Icotinib Neratinib Dacomitinib Fostamatinib Zalutumumab Brigatinib Olmutinib Zanubrutinib Abivertinib	Choriocarcinoma Gastric cancer Bladder cancer Oral cancer Glioma Laryngeal cancer Cervical cancer Esophageal cancer
	FGA	fibrinogen alpha chain	Platelet degranulation Common Pathway of Fibrin Clot Formation Integrin cell surface interactions Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) MAP2K and MAPK activation Regulation of TLR by endogenous ligand Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Post-translational protein phosphorylation Signaling downstream of RAS mutants Signaling by RAF1 mutants Amyloid fiber formation	Alteplase Reteplase Anistreplase Tenecteplase Sucralfate Zinc Alfimeprase Ancrod EP-2104R Lanoteplase Thrombin Prothrombin Human thrombin Thrombin alfa Anti-inhibitor coagulant complex Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Afibrinogenemia; Dysfibrinogenemia Inherited thrombophilia Familial amyloidosis
	PTPRB	protein tyrosine phosphatase receptor type B	Neutrophil degranulation	{4-[2-BENZYL-3-METHOXY-2-(METHOXYCARBONYL)-3-OXOPROPYL]PHENYL}SULFAMIC ACID (4-{4-[(TERT-BUTOXYCARBONYL)AMINO]-2,2-BIS(ETHOXYCARBONYL)BUTYL}PHENYL)SULFAMIC ACID {4-[2,2-BIS(5-METHYL-1,2,4-OXADIAZOL-3-YL)-3-PHENYLPROPYL]PHENYL}SULFAMIC ACID (4-ETHYLPHENYL)SULFAMIC ACID Razuprotafib
	CSK	C-terminal Src kinase	GAB1 signalosome Phosphorylation of CD3 and TCR zeta chains Integrin signaling PD-1 signaling MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Negative regulation of FLT3	Dasatinib Staurosporine TG-100801 Fostamatinib
	EPHA2	EPH receptor A2	EPH-Ephrin signaling EPH-Ephrin signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse EPH-ephrin mediated repulsion of cells EPH-ephrin mediated repulsion of cells	Dasatinib Phosphoaminophosphonic Acid-Adenylate Ester Regorafenib Fostamatinib
	DSP	desmoplakin	Apoptotic cleavage of cell adhesion proteins Neutrophil degranulation Keratinization Formation of the cornified envelope	Zinc Artenimol Zinc acetate	Arrhythmogenic right ventricular cardiomyopathy (ARVC) Naxos disease and Carvajal syndrome Striate palmoplantar keratoderma Skin fragility-woolly hair syndrome Epidermolysis bullosa simplex, including: Epidermolysis bullosa simplex, Dowling-Meara type (EBS-DM); Epidermolysis bullosa simplex, Koebner type (EBS-K); Epidermolysis bullosa simplex, Weber-Cockayne type (EBS-WC); Epidermolysis bullosa simplex with mottled pigmentation (EBS-MP); Epidermolysis bullosa simplex with migratory circinate erythema; Epidermolysis bullosa simplex, recessive; Epidermolysis bullosa, lethal acantholytic
	P2RX4	purinergic receptor P2X 4	Elevation of cytosolic Ca2+ levels Platelet homeostasis Purinergic signaling in leishmaniasis infection	Promethazine Eslicarbazepine acetate Eslicarbazepine
	JUP	junction plakoglobin	Adherens junctions interactions VEGFR2 mediated vascular permeability Neutrophil degranulation Keratinization Formation of the cornified envelope	Zinc Zinc acetate	Arrhythmogenic right ventricular cardiomyopathy (ARVC) Naxos disease and Carvajal syndrome
	VIM	vimentin	Caspase-mediated cleavage of cytoskeletal proteins Striated Muscle Contraction Interleukin-4 and Interleukin-13 signaling Chaperone Mediated Autophagy Late endosomal microautophagy Aggrephagy	Artenimol Phenethyl Isothiocyanate
	CTNNB1	catenin beta 1	Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade TCF dependent signaling in response to WNT Formation of the beta-catenin:TCF transactivating complex Formation of the beta-catenin:TCF transactivating complex LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Apoptotic cleavage of cell adhesion proteins Deactivation of the beta-catenin transactivating complex Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Ca2+ pathway Adherens junctions interactions Binding of TCF/LEF:CTNNB1 to target gene promoters Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability Myogenesis Myogenesis Signaling by GSK3beta mutants S33 mutants of beta-catenin aren't phosphorylated S37 mutants of beta-catenin aren't phosphorylated S45 mutants of beta-catenin aren't phosphorylated T41 mutants of beta-catenin aren't phosphorylated RHO GTPases activate IQGAPs Transcriptional Regulation by VENTX InlA-mediated entry of Listeria monocytogenes into host cells RUNX3 regulates WNT signaling	Urea	Gastric cancer Colorectal cancer Endometrial Cancer Pilomatricoma; Epithelioma calcificans of Malherbe Thyroid cancer Hepatocellular carcinoma
	P2RX6	purinergic receptor P2X 6	Elevation of cytosolic Ca2+ levels Platelet homeostasis	Promethazine

Search Results for: CDH5